These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23896027)

  • 1. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients.
    Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
    Exp Cell Res; 2013 Nov; 319(18):2812-21. PubMed ID: 23896027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
    Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
    J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab.
    Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
    J Microsc; 2014 Apr; 254(1):19-30. PubMed ID: 24499016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting CD20-rituximab specific interactions on lymphoma cells using atomic force microscopy.
    Li M; Liu L; Xi N; Wang Y; Dong Z; Li G; Xiao X; Zhang W
    Sci China Life Sci; 2010 Oct; 53(10):1189-95. PubMed ID: 20953941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy.
    Li M; Xiao X; Liu L; Xi N; Wang Y
    J Immunol Methods; 2016 Sep; 436():41-9. PubMed ID: 27374866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.
    Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
    Scanning; 2013; 35(1):40-6. PubMed ID: 22890585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
    Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
    Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.
    Kawabata KC; Ehata S; Komuro A; Takeuchi K; Miyazono K
    Oncogene; 2013 Apr; 32(16):2096-106. PubMed ID: 22665052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20 as a target for therapeutic type I and II monoclonal antibodies.
    Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
    Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
    Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.